Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | CANOPY-A: canakinumab for early stage NSCLC

David Spigel • 28 May 2020
ASCO 2020
Lung Cancer Non-Small Cell Lung Cancer Antibodies Canakinumab
CANOPY-A

David R. Spigel, MD, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, discusses the ongoing CANOPY-A study (NCT03447769) aiming to determine the efficacy of canakinumab, an interleukin-beta inhibitor in early stage non-small cell lung cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from David Spigel

2:00
Lung cancer updates at ASCO 2021
David Spigel • 26 May 2021
4:46
5-year survival outcomes from the PACIFIC trial
David Spigel • 26 May 2021
2:31
RESILIENT: liposomal irinotecan in relapsed SCLC
David Spigel • 28 May 2020
4:58
Discussion on the ADAURA study
David Spigel • 28 May 2020

Related Videos

0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals